Profile data is unavailable for this security.
About the company
Zhejiang Huahai Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, manufacture and sales of generic drugs, biological drugs, innovative drugs and specialty active pharmaceutical ingredients (APIs) in multiple dosage forms. The Company's pharmaceutical preparations and APIs cover cardiovascular, mental disorder, nervous system and anti-infection fields. The Company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, oseltamivir phosphate capsules, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, febuxostat tablets and torsemide injection. The Company also provides technical services and pharmaceutical import and export trade business.
- Revenue in CNY (TTM)9.14bn
- Net income in CNY1.01bn
- Incorporated2001
- Employees8.22k
- LocationZhejiang Huahai Pharmaceutical Co LtdXunqiao, Linhai CityTAIZHOU 317024ChinaCHN
- Phone+86 57 685991096
- Fax+86 57 685016010
- Websitehttps://www.huahaipharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kangmei Pharmaceutical Co Ltd | 4.97bn | 244.14m | 26.62bn | 4.41k | 108.54 | 3.77 | -- | 5.35 | 0.0177 | 0.0177 | 0.3596 | 0.5095 | 0.3447 | 1.39 | 2.50 | 1,127,547.00 | 1.71 | -17.60 | 2.59 | -32.24 | 21.52 | -72.78 | 4.96 | -101.19 | 0.8735 | -- | 0.1544 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
Hubei Jumpcan Pharmaceutical Co Ltd | 9.06bn | 2.82bn | 27.43bn | 5.23k | 9.69 | 2.03 | -- | 3.03 | 3.07 | 3.07 | 9.85 | 14.65 | 0.5262 | 3.09 | 4.60 | 1,732,306.00 | 16.41 | 16.23 | 21.92 | 20.88 | 79.06 | 82.64 | 31.20 | 24.42 | 3.13 | -- | 0.116 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.14bn | 1.01bn | 28.75bn | 8.22k | 28.02 | 3.27 | -- | 3.14 | 0.6995 | 0.6995 | 6.32 | 6.00 | 0.4681 | 1.09 | 3.23 | 1,112,139.00 | 5.16 | 5.67 | 7.35 | 8.07 | 60.27 | 60.52 | 11.03 | 11.61 | 0.8547 | 5.52 | 0.4506 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
Gan & Lee Pharmaceuticals | 2.69bn | 504.82m | 29.23bn | 4.48k | 55.52 | 2.66 | -- | 10.85 | 0.8759 | 0.8759 | 4.65 | 18.26 | 0.2375 | 0.8825 | 8.31 | 600,884.60 | 4.45 | 8.30 | 4.78 | 8.83 | 72.15 | 85.39 | 18.75 | 26.44 | 7.05 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
Shanghai Junshi Biosciences Co Ltd | 1.62bn | -1.93bn | 29.43bn | 2.53k | -- | 5.23 | -- | 18.18 | -1.96 | -1.96 | 1.64 | 6.58 | 0.1422 | 0.8649 | 3.45 | 630,414.10 | -18.42 | -18.87 | -23.01 | -23.11 | 67.77 | 69.13 | -129.54 | -88.41 | 1.87 | -36.65 | 0.2801 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
Bluestar Adisseo Co | 14.12bn | 626.36m | 31.24bn | 2.73k | 49.88 | 2.06 | -- | 2.21 | 0.2336 | 0.2336 | 5.26 | 5.65 | 0.6549 | 5.03 | 7.54 | 5,163,249.00 | 2.91 | 5.28 | 3.52 | 6.94 | 26.31 | 30.31 | 4.44 | 8.76 | 1.08 | 6.12 | 0.0989 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
Xiamen Amoytop Biotech Co Ltd | 2.39bn | 657.61m | 32.99bn | 1.96k | 50.17 | 16.38 | -- | 13.82 | 1.62 | 1.62 | 5.87 | 4.95 | 1.12 | 0.8751 | 5.89 | 1,217,627.00 | 30.81 | 17.96 | 35.47 | 21.02 | 92.97 | 90.48 | 27.55 | 19.17 | 3.34 | -- | 0.005 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.10bn | 921.94m | 33.19bn | 4.62k | 29.87 | 4.38 | -- | 4.10 | 1.19 | 1.19 | 10.50 | 8.14 | 0.7275 | 2.78 | 3.17 | 1,753,354.00 | 8.13 | 8.96 | 13.61 | 12.80 | 44.45 | 40.82 | 11.18 | 10.67 | 1.26 | -- | 0.1897 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
Holder | Shares | % Held |
---|---|---|
Essence Fund Co., Ltd.as of 31 Dec 2023 | 8.90m | 0.61% |
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 8.64m | 0.59% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 7.41m | 0.51% |
China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 6.43m | 0.44% |
Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 4.30m | 0.30% |
Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 3.87m | 0.27% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 3.85m | 0.27% |
Galaxy Asset Management Co., Ltd.as of 31 Dec 2023 | 3.53m | 0.24% |
Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 3.06m | 0.21% |
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 2.41m | 0.17% |